Skip to main content
Evidence Snapshot

Sigma non-opioid intracellular receptor 1

CHEMBL287 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:12:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL287
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sigma non-opioid intracellular receptor 1 as ChEMBL target CHEMBL287, mapped to UniProt Q99720. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sigma non-opioid intracellular receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL287
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99720
Sigma non-opioid intracellular receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sigma non-opioid intracellular receptor 1 matters

As of 2026-09-13

Sigma non-opioid intracellular receptor 1 is reviewed as Sigma non-opioid intracellular receptor 1 (UniProt Q99720); Sigma non-opioid intracellular receptor 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 146 approved drugs, 4872 compounds, and 605 assays, with lead potency reaching pChEMBL 11.0.

Protein context
Sigma non-opioid intracellular receptor 1

Sigma non-opioid intracellular receptor 1 Sequence length is 223 aa.

Review this target as Sigma non-opioid intracellular receptor 1, mapped to UniProt Q99720. Sequence length is 223 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q99720 Protein
Disease context
pain

Sigma non-opioid intracellular receptor 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DEXTROMETHORPHAN HYDROBROMIDE, PENTAZOCINE HYDROCHLORIDE.

Start review with pain because it currently carries approved-linked support. Linked drugs include DEXTROMETHORPHAN HYDROBROMIDE, PENTAZOCINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 146 approved drugs, 4872 compounds, and 605 assays for this target. The dominant activity type is KI. CHEMBL372700 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL372700 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
146 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sigma non-opioid intracellular receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q99720, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why pain is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4872
Total Compounds
605
Total Assays
146
Approved Drugs
IC50: 1885.0, KI: 4504.0, KD: 18.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL372700
11.0 Ki
No preferred name
CHEMBL5432062
10.9 Ki
No preferred name
CHEMBL3763396
10.5 Ki
10.4 Ki
No preferred name
CHEMBL365842
10.4 Ki

Approved Drugs

Structure Compound First Approval
2016
BREXPIPRAZOLE
CHEMBL2105760
2015
2011
ILOPERIDONE
CHEMBL14376
2009
TETRACAINE
CHEMBL698
2005
2004
TEGASEROD MALEATE
CHEMBL1516474
2002
1998
CITALOPRAM
CHEMBL549
1998
QUETIAPINE
CHEMBL716
1997
RALOXIFENE
CHEMBL81
1997
1996
DONEPEZIL
CHEMBL502
1996
FLUVOXAMINE
CHEMBL814
1994
CISAPRIDE
CHEMBL1729
1993
TERBINAFINE
CHEMBL822
1992
SERTRALINE
CHEMBL809
1991
TICLOPIDINE
CHEMBL833
1991
REMOXIPRIDE
CHEMBL22242
1990
CLOMIPRAMINE
CHEMBL415
1989
ASTEMIZOLE
CHEMBL296419
1988
NAFTIFINE
CHEMBL626
1988
TERCONAZOLE
CHEMBL1714574
1987
FLUOXETINE
CHEMBL41
1987
BUSPIRONE
CHEMBL49
1986
LEVOBUNOLOL
CHEMBL1201237
1985
1985
AMIODARONE
CHEMBL633
1985
LABETALOL
CHEMBL429
1984
DEXTROMETHORPHAN
CHEMBL52440
1982
TRAZODONE
CHEMBL621
1981
DEXCHLORPHENIRAMINE
CHEMBL1201353
1981
SULOCTIDIL
CHEMBL404849
1979
TIMOLOL
CHEMBL499
1978
CLEMASTINE
CHEMBL1626
1977
TAMOXIFEN
CHEMBL83
1977
LOPERAMIDE
CHEMBL841
1976
PROGESTERONE
CHEMBL103
1976
1976
PRAMOXINE
CHEMBL1198
1976
OXYBUTYNIN
CHEMBL1231
1975
PYRILAMINE
CHEMBL511
1973
MAZINDOL
CHEMBL781
1973
DIMENHYDRINATE
CHEMBL1200406
1972
DOXEPIN
CHEMBL1628227
1969
FENTANYL
CHEMBL596
1968
AMANTADINE
CHEMBL660
1968
1967
PENTAZOCINE
CHEMBL100116
1967
DIPHENIDOL
CHEMBL936
1967
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:12:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL287